2025 · 3rd Quarter (July 1 - Sep 30)

ALNYLAM PHARMACEUTICALS, INC.

Filed by TODD STRATEGY GROUP.

Open official filing

Source-reported fields

Filing overview

Type: 3rd Quarter - Report
Posted: Oct 21, 2025
Income: $60,000.00
Expenses: Not reported
Registrant: TODD STRATEGY GROUP
Client: ALNYLAM PHARMACEUTICALS, INC.
Filing UUID: f53dc0d1-125b-4b93-abc4-7ad5b37af3e6
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

Medicare and Medicaid Issues H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.

Literal federal measure citations: H.R.1672, H.R.946

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.